Unknown

Dataset Information

0

Mitochondrial dysfunction enhances cisplatin resistance in human gastric cancer cells via the ROS-activated GCN2-eIF2?-ATF4-xCT pathway.


ABSTRACT: Mitochondrial DNA mutations and defects in mitochondrial enzymes have been identified in gastric cancers, and they might contribute to cancer progression. In previous studies, mitochondrial dysfunction was induced by oligomycin-enhanced chemoresistance to cisplatin. Herein, we dissected the regulatory mechanism for mitochondrial dysfunction-enhanced cisplatin resistance in human gastric cancer cells. Repeated cisplatin treatment-induced cisplatin-resistant cells exhibited high SLC7A11 (xCT) expression, and xCT inhibitors (sulfasalazine or erastin), xCT siRNA, or a GSH synthesis inhibitor (buthionine sulphoximine, BSO) could sensitize these cells to cisplatin. Clinically, the high expression of xCT was associated with a poorer prognosis for gastric cancer patients under adjuvant chemotherapy. Moreover, we found that mitochondrial dysfunction enhanced cisplatin resistance and up-regulated xCT expression, as well as intracellular glutathione (GSH). The xCT inhibitors, siRNA against xCT or BSO decreased mitochondrial dysfunction-enhanced cisplatin resistance. We further demonstrated that the upregulation of the eIF2?-ATF4 pathway contributed to mitochondrial dysfunction-induced xCT expression, and activated eIF2? kinase GCN2, but not PERK, stimulated the eIF2?-ATF4-xCT pathway in response to mitochondrial dysfunction-increased reactive oxygen species (ROS) levels. In conclusion, our results suggested that the ROS-activated GCN2-eIF2?-ATF4-xCT pathway might contribute to mitochondrial dysfunction-enhanced cisplatin resistance and could be a potential target for gastric cancer therapy.

SUBMITTER: Wang SF 

PROVIDER: S-EPMC5342041 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Mitochondrial dysfunction enhances cisplatin resistance in human gastric cancer cells via the ROS-activated GCN2-eIF2α-ATF4-xCT pathway.

Wang Sheng-Fan SF   Chen Meng-Shian MS   Chou Yueh-Ching YC   Ueng Yune-Fang YF   Yin Pen-Hui PH   Yeh Tien-Shun TS   Lee Hsin-Chen HC  

Oncotarget 20161101 45


Mitochondrial DNA mutations and defects in mitochondrial enzymes have been identified in gastric cancers, and they might contribute to cancer progression. In previous studies, mitochondrial dysfunction was induced by oligomycin-enhanced chemoresistance to cisplatin. Herein, we dissected the regulatory mechanism for mitochondrial dysfunction-enhanced cisplatin resistance in human gastric cancer cells. Repeated cisplatin treatment-induced cisplatin-resistant cells exhibited high SLC7A11 (xCT) expr  ...[more]

Similar Datasets

| S-EPMC10572406 | biostudies-literature
| S-EPMC5777716 | biostudies-literature
| S-EPMC6872934 | biostudies-literature
| S-EPMC6275069 | biostudies-literature
| S-EPMC6991694 | biostudies-literature
| S-EPMC10138370 | biostudies-literature
| S-EPMC6892979 | biostudies-literature
| S-EPMC9239699 | biostudies-literature
| S-EPMC7811044 | biostudies-literature
| S-EPMC5065394 | biostudies-literature